ClinicaliQ Trial Snapshot
- An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants — Recruiting • Phase III • Rheumatology • NCT05835310.
- Anifrolumab (an interferon blocker) tested for safety and effectiveness in children with moderate to severe lupus.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
A Study to Evaluate the Pharmacokinetics (PK), Pharmacodynamics (PD), Efficacy, and Safety of Anifrolumab in Children with Moderate to Severe Active Systemic Lupus Erythematosus (SLE) Conditions: Systemic Lupus Erythematosus Interventions: Anifrolumab, Placebo Lead Sponsor: AstraZeneca Planned Enrollment: 100 participants